US 9,539,299 B2Granted

Combination therapy with WT1 peptide vaccine and temozolomide

AssigneeInternational Institute of Cancer Immunology, Inc.

InventorsHaruo Sugiyama, Toshiki Yoshimine, Akihiro Tsuboi, Naoya Hashimoto

Life of this patent

Estimating the term…

Abstract

The present invention relates to combination therapy for cancer with a WT1 peptide vaccine and temozolomide.

Claims4

Dependent claims

A method for treating a WT-1-expressing cancer, comprising administering therapeutically effective doses of a WT1 peptide and temozolomide to a human patient after radiation therapy in need thereof, wherein the WT1 peptide is

Dependencies are inferred from the claim text.

Facts

Application: 13/665,597Filed 31 Oct 2012 · us provisional application
Priority: 27 Oct 2011
Published: US 2013/0225502 A129 Aug 2013
Granted: 10 Jan 2017
Term ends: Not estimatedThe source records don’t support an estimate.

Classification4 codes

A61K 38/08
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: peptides having 5 to 11 amino acids
A61K 31/495
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having six-membered rings with two or more nitrogen atoms as the only ring…
A61K 39/001153
Transcription factors, e.g. SOX or c-MYC: wilms tumor 1 [WT1]
A61K
Medicines and medical preparations

Family

Application61/552,209Us provisional application · filed 27 Oct 2011
US 2013/0225502 A1Pre-grant publication · published 29 Aug 2013
US 9,539,299 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results